Pancreatic cancer is a deadly disease with the majority of patients surviving less than one year. Despite huge advances in other oncology indications, treatment options for pancreatic cancer remain…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different systems and organs of the body and manifest with a wide spectrum of clinical symptoms. Lupus nephritis (LN) is…
Osteoarthritic (OA) pain represents the second-largest segment of the overall chronic pain market, affecting more than 70 million patients with OA in the G7. The OA pain market represents a…
Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR- and ALK-…
Despite the wide range of treatment options available, metastatic non-small-cell lung cancer (NSCLC) remains a major cause of cancer-related death. For patients with metastatic (EGFR- and ALK-…
Muscular dystrophies (MDs) are a spectrum of genetic disorders characterized by muscle weakness that in severe disease forms can lead to loss of ambulation and early death. MDs share common…
The atopic dermatitis (AD) market is poised to undergo a revolution owing to recent advances in understanding of disease pathology, the recent approval of topical crisaborole (Pfizer’s Eucrisa)…
Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently…
Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic…
Despite the extensive armamentarium of chronic pain therapies, which is increasingly subject to generic competition, the chronic pain market continues to represent a notable commercial…
Painful diabetic neuropathy (PDN), a subset of diabetic neuropathy; affects approximately seven million people in the United States and major European markets. The primary goal of treating PDN is…
The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several…
Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is high unmet need for drugs that can effectively control the disease. DRG’s Type 2 Diabetes Unmet…